

DAFTAR PUSTAKA

1. Cunningham L, Bloom, Dashe. *Hypertensive Disorders*. Williams Obstetric 24 ed. New York: Mc Graw Hill; 2018. p.1086-8
2. ACOG. *Hypertension in pregnancy*. Washington : the American College of Obstetricians and Gynecologists; 2013.p. 22
3. HKFM POGI. Diagnosis dan Tata Laksana Pre-Eklamsia. 2016
4. Saito S. *Preeclampsia, Basic, Genomic, and Clinical*. Springer. 2018
5. Adhi Pribadi. Preeklampsia “Stoppable”. Sagung Seto. 2019
6. Huppertz B. Vascular development in the placenta. Dalam : Kay HH ND, Wang Y. Placenta from development to disease. Wet sussex : Blackwell's ; 2011. H.36-42
7. English FA, Kenny LC, McCarthy FP. Risk factors and effective management of preeclampsia. Integr Blood Press Control. 2015;8;7-12
8. Hladunewich M, Karumanchi A, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am soc Nephrol. 2007;2:543-9
9. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet, 2010;376(9741):631-644
10. Lyall F, Belfort B. *Pre-eclampsia Etiology and Clinical Practice*, Cambridge. UK: Cambridge University Press, The Edinburgh Building; 2007.
11. Akhilesh M, Mahalingam V, Nalliah S, Ali RM, Ganesalingam , Haleagrahara N. Participation of hypoxia-inducible factor-1a in the pathogenesis of preeclampsia-related placental ischemia and its potential as a marker for preeclampsia. Biomarker and Genom Med. 2014 June; 6(121-125).
12. Rath G, Aggarwa , Jawanjal P, Tripathi R, Batra A. HIF-1 Alpha and Placental Growth Factor in Pregnancies Complicated With Preeclampsia: A Qualitative and Quantitative Analysis. J of Clin Lab Anal. 2016; 30(75-83).

13. Laskowska M. Preeclampsia-aetiopathogenesis and clinical management. *Curr Pharm Biotechnol.* 2018;19(10): 762-763.
14. Travaglino A, et al. Placental morphology, apoptosis, angiogenesis and epithelial mechanisms in early-onset preeclampsia. *Eur J Obstet Gynecol Reprod Biol.* 2019 Mar;234: 200-206.
15. Angsar MD. Hipertensi dalam kehamilan. Dalam: Ilmu kebidanan Sarwono Prawirohardjo. Edisi ke-4. Jakarta: PT Bina Pustaka Sarwono Prawirohardjo; 2013. h. 530-50.
16. Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics dan therapies. *Nat rev Nephrol.* 2019 feb 21.
17. Malik A, Jee B, Gupta SK. Preeclampsia: disease biology and burden, its management strategies with reference to India. *International Society for the study of hypertension in pregnancy.* 2018 Nov 02. 2019 (15): 23-31
18. Krisnadi SR, Mose JC, Effendi JS. Hipertensi Kehamilan. Dalam: Pedoman diagnosis dan terapi obstetric dan ginekologi rumah sakit Dr. Hasan Sadikin. Edisi ke 2. Bagian pertama. Bandung: FK UNPAD; 2005. h. 60-70.
19. Baumwell S, Karumanchi SA. Pre-eclampsia: clinical manifestasions and molecular mechanisms. *Nephron Clin Pract.* 2007 Jun 6. 106(2): 72-81.
20. Mayrink J, Costa ML, Cecatti JG. Preeclampsia in 2018: revisiting cocepts, physiopathology, and prediction. *The Scientific World Journal.* 2018 Dec 6. 1-9.
21. Brosens I, Brosens JJ, Muter J, Puttemans P, Benagiano G. Preeclampsia: the role of persistent endothelial cells in uteroplacental arteries. *Am J Obstet Gynecol.* 2019 Feb 6.
22. Brown, C. M., & Garovic, V. D. (2014). Drug Treatment of Hypertension in Pregnancy. *Drugs.* 2014; 74(3), 283–296.

23. Sibai BM. Hypertension. In: Gabbe SG, Niebyl JR, Simpson JL, Landon MB, Galan HL, Jauniaux ERM, et al, editors. *Obstetrics normal and problem pregnancies*. 7th ed. Philadelphia: Elsevier; 2017. p. 661-705
24. Townsend, Rosemary. O'Brien, Patrick. Khalil, Asma. *Current best practice in the management of hypertensive disorders in pregnancy*. Integrated Blood Pressure Control. London. 2016
25. Kanasaki Keizo, Kalluri Raghu. *The biology of preeclampsia*. International Society of Nephrology. NIH Public Access. 2009
26. Bernandes TP, et al. Recurrent risk of preeclampsia in a linked population-based cohort: effects of first pregnancy maximum diastolic blood pressure and gestational age. International Society for the study of hypertension in pregnancy. 2018 Nov 02. 2019(15): 32-36.
27. Killion, M. (2015). New Hypertension in Pregnancy Guidelines. MCN, The American Journal of Maternal/Child Nursing.2015. 40(2), 128.
28. Palei AC, Spradley FT, Warrington JP, George EM, Granger JP. Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol (Oxf).2013 Jul. 208 (3): 224-33
29. Brown, C. M., & Garovic, V. D. (2014). Drug Treatment of Hypertension in Pregnancy. Drugs. 2014. 74(3), 283–296.
30. Welsh A, editor. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. London: Royal College of Obstetricians and Gynaecologists; 2011. p. 3-96.
31. Lu HQ, Hu R. The role of immunity in the pathogenesis and development of preeclampsia. Scand J Immunol. 2019 Feb 9.
32. Indriana N, Prasetyorini N, Wahyudi I. HIF2 α Placental Expression in Intrauterine Growth Restriction Preeclampsia. J Dent and Med Sci.2015;14 (4)

33. Iriyama T, Wang , Parchim N, Song , Blackwell SC, Sibai B, et al. Hypoxia-Independent Upregulation of Placental Hypoxia Inducible Factor-1 α Gene Expression Contributes to the Pathogenesis of Preeclampsia. Hyper AHA J. 2015 April
34. Tal R, Shaish A, Barshack , Polak-Charcon S, Afek A, Volkov A, et al. Effects of Hypoxia-Inducible Factor-1a Overexpression in Pregnant Mice. Amer J of Path. 2010 December; 177(6).
35. Galbiati S, Inversetti A, Causarano V, Stenirri S, Soriani N. HIF1A and MIF as potential predictive mRNA biomarkers of pre-eclampsia: a longitudinal prospective study in high risk population. Clin Chem Lab Med. 2015; 53(9).
36. Vermaa S, Pillay P, Naickerb T, Moodley J, Mackraj I. Placental hypoxia inducible factor -1a & CHOP immuno-histochemical expression relative to maternal circulatory syncytiotrophoblast micro-vesicles in preeclamptic and normotensive pregnancies. Euro J of Obs & Gyn Rep Bio. 2018; 220(18-24).
37. Tal R. The Role of Hypoxia and Hypoxia-Inducible Factor-1Alpha in Preeclampsia Pathogenesis. Bio of Rep. 2012; 87(6).
38. Lai H, Liu H. Expression and meaning analysis of HIF-1 α and HSP70 in preeclamptic placenta. Biomed Res. 2018 December; 29(6).
39. Nava-Salazar S, Sánchez-Rodríguez EN, Mendoza-Rodríguez A, Moran , Juan F Romero-Arauz , A Cerbón M. Polymorphisms in the hypoxia-inducible factor 1 alpha gene in Mexican patients withpreeclampsia: A case-control study. BMC Res Not. 2011; 4(68).
40. El-Sayed AAF. Preeclampsia: A review of the pathogenesis and possible management strategies based on its pathophysiological derangements. Taiwan J Obs Gyn. 2017 July; 56(593-598).
41. Liu W, Wang SJ, Lin QD. Study on the Expressions of PHD and HIF in Placentas from Normal Pregnant Women and Patients with Preeclampsia. Int. J. Biol. Sci.. 2014; 10

- 
42. Caniggia I, Mostachfi H, Winter J, Gassmann M, Lye SJ, Kuliszewski M, Post M. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). *J Clin.Invest* 2000; 105(5):577–587.
 43. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. *J Biol Chem* 2002; 277(46):43799–43808.
 44. Kanasaki Keizo, Kalluri Raghu. *The biology of preeclampsia*. International Society of Nephrology. NIH Public Access. 2009.
 45. Rolfo A, Many A, Racano A, Tal R, Tagliaferro A, et al. Abnormalities in Oxygen Sensing Define Early and Late Onset Preeclampsia as Distinct Pathologies. *PLoS ONE* 2010; 5(10): e13288.
 46. Wantania J, Bakri S, Pandelaki K, Chalid M. (2013). Altered level of Soluble fms-like Tyrosine Kinase 1 (sFlt1) and Hypoxia Inducible Factor-1 α in Normotensive Pregnancy and Preeclampsia. *Indones Biomed J* 2013; 5(2):121-8.
 47. Lindheimer MD, and Romero R. 2007. Emerging Roles of Antiangiogenic and Angiogenic Proteins in Pathogenesis and Prediction of Preeclampsia. *Hypertens* 50:35-36.
 48. Eiland E, Nzerue C, Faulkner M. 2012. Preeclampsia 2012. *J Preg*.
 49. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications *BMJ*. 2019;366:1-15.
 50. Gathiram P, Moodley J. Pre-eclampsia: its pathogenesis and pathophysiology. *Cardiovascular journal of Africa*. 2016;27(2):71-8.
 51. Davutoglu EA, Firat AA, Ozel A, Yilmaz N, Uzun I, Yuksel IT, et al. Evaluation of maternal serum hypoxia inducible factor-1a, progranulin and syndecan-1 levels in pregnancies with early and late onset preeclampsia. *The Journal of Maternal Fetal & Neonatal*. 2017;2017:1-7.

52. Sriyanti R, Mose JC, Masrul, N. S. The difference in maternal serum Hypoxia-Inducible Factors-1a levels between early onset and late onset preeclampsia. Journal of Medical Science. 2019;7(13):2133-7.
53. Galbiati S, Inversetti A, Causarano V, Stenirri S, Soriani N, Ambrosi A. HIF1A and MIF as potential predictive mRNA biomarkers of pre-eclampsia: a longitudinal prospective study in high risk population Clin Chem Lab Med. 2015;53(9):1339-47.
54. Lai H, Liu H. Expression and meaning analysis of HIF-1a and HSP70 in preeclamptic placenta. Biomedical Research. 2018;29(6):1240-3.
55. Roza Sriyanti, Johanes C. Mose, Netti Suharti. The Difference in Maternal Serum Hypoxia-Inducible Factors-1 α Levels between Early Onset and Late-Onset Preeclampsia. Maced J Med Sci. 2019 Jul 15; 7(13): 2133–2137.
56. Anna W 'ojtowicz , Małgorzata Zembala-Szczerba, Dorota Babczyk, Monika Kołodziejczyk-Pietruszka, Olga Lewaczy nska, Hubert Huras. Early- and Late-Onset Preeclampsia: A Comprehensive Cohort Study of Laboratory and Clinical Findings according to the New ISHHP Criteria. International Journal of Hypertension. Volume 2019, Article ID 4108271, 9 pages <https://doi.org/10.1155/2019/4108271>
57. Sahay A.S, D.P. Sundrani, G.N. Wagh, S.S. Mehendale , S.R. Joshi. Neurotropin levels in different regions of the placenta and their association with birth outcome and blood pressure. 2015. <http://dx.doi.org/10.1016/j.placenta.2015.06.006>. Elsevier.
58. Husen, D & Polin, A. 2012. Factors Influencing Maternal Mortality from Severe Preeclampsia and Eclampsia. Maj Obstet Ginekolog Indonesia 2012; 36-2: 90-4
59. Denantika O, Serudji J, Revilla G. 2015. Hubungan Status Gravida dan Usia Ibu terhadap Kejadian Preeklampsia di RSUP Dr. M. Djamil Padang Tahun 2012-2013. Jurnal Kesehatan Andalas 4(1).
60. El Shahat AM, Ahmed AB, Ahmed MR, Mohamed HS. 2013. Maternal serum leptin as a marker of preeklampsia. Arch Gynecol Obstet 288(6):1317-1322.

61. Ario Danianto, Ernawati. Perbedaan Kadar IL-10 pada Preeklampsia Tipe Dini dan Lambat Majalah Obstetri & Ginekologi, Vol. 23 No. 3 September - Desember 2015 : 106-111
62. Ebru Alici Davutoglu et al. Evaluation of maternal serum hypoxia inducible factor-1a, programulin and syndecan-1 levels in pregnancies with early- and late-onset preeclampsia. The Journal Of Maternal-Fetal & Neonatal Medicine 2018, VOL. 31, NO. 15.
63. Bobek G, Surmon L, Mirabito KM, et al. Placental regulation of inflammation and hypoxia after TNF- α infusion in mice. Am J Reprod Immunol. 2015;74: 407–418.
64. Richard DE, Berra E & Pouyssegur J (2000) Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1a in vascular smooth muscle cells. *J Biol Chem*, 275, 26765–26771.
65. Poston L, Raijmakers TM. Trophoblast oxidative stress, antioxidants and pregnancy outcome—a review. *Placenta*. 2004;18:S72–S78.
66. Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. *J Soc Gynecol Investig*. 2004;11:342–352.
67. Raijmakers MT, Peters WH, Steegers EA, et al. NAD(P)H oxidase associated superoxide production in human placenta from normotensive and pre-eclamptic women. *Placenta*. 2004;25:S85–S89.
68. Raymond D, Peterson E. A Critical Review of Early-Onset and Late-Onset Preeclampsia. Obstetrical and Gynecological Survey by Lippincott Williams & Wilkins. 2011. Volume 66, Number 8.